FLT3LG and IFITM3P6 Consolidate T Cell Activity in the Bone Marrow Microenvironment and Are Prognostic Factors in Acute Myelocytic Leukemia

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Sep 9

PMID 36081495

Authors

Haiyan Chen

Meng Wu

Hongping Xia

Songjie Du

Guoren Zhou

Guangfeng Long

Yanan Zhu

Xu Huang

Daheng Yang

Affiliations

Soon will be listed here.

Abstract

Acute myelocytic leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage. CD4+ and CD8+ T cells play pivotal roles in influencing AML progression but are functionally suppressed in the bone marrow microenvironment. We aimed to find hub genes related to T cell exhaustion and suppression, thereby providing evidence for immunotherapy. In this study, gene transcriptome expression data from TCGA and TARGET databases were utilized to find key genes. Firstly, CIBERSORT immune cell infiltration algorithm and WGCNA method were used to identify CD4+ and CD8+ T cells-related genes. Univariate and multivariate cox regression analyses were then introduced to construct the overall survival prognosis model and included hub genes. The ESTIMATE and ssGSEA scoring methods were used to analyze the correlation between the hub genes and immune activity. Single-cell transcriptome analysis was applied to detect the immune cells expressing hub genes, hence, to detect exact mechanisms. Consequently, FLT3LG and IFITM3P6 were determined to be positively correlated with patients' overall survival and microenvironment immune activity. Further study suggested FLT3-FLT3LG and IFITM3P6-miR-6748-3p-CBX7 signaling axes were involved in CD4+ and CD8+ T cells activation. This may be one of the mechanisms of T cells suppression in AML.

Citing Articles

Li Z, Jin P, Xiang R, Li X, Shen J, He M Front Immunol. 2024; 15:1408109.

PMID: 39346926 PMC: 11428106. DOI: 10.3389/fimmu.2024.1408109.

References

Zhao K, Yang H, Kang H, Wu A . Identification of Key Genes in Thyroid Cancer Microenvironment. Med Sci Monit. 2019; 25:9602-9608. PMC: 6929555. DOI: 10.12659/MSM.918519. View

De Kouchkovsky I, Abdul-Hay M . 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016; 6(7):e441. PMC: 5030376. DOI: 10.1038/bcj.2016.50. View

Hernandez-Camarero P, Lopez-Ruiz E, Marchal J, Peran M . Cancer: a mirrored room between tumor bulk and tumor microenvironment. J Exp Clin Cancer Res. 2021; 40(1):217. PMC: 8240272. DOI: 10.1186/s13046-021-02022-5. View

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Zheng X, Gong Y . Functions of RNA N-methyladenosine modification in acute myeloid leukemia. Biomark Res. 2021; 9(1):36. PMC: 8130309. DOI: 10.1186/s40364-021-00293-w. View

Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L . A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2013; 10(2):93-5. PMC: 3911877. DOI: 10.1038/nchembio.1432. View

Buckley S, Kirtane K, Walter R, Lee S, Lyman G . Patient-reported outcomes in acute myeloid leukemia: Where are we now?. Blood Rev. 2017; 32(1):81-87. DOI: 10.1016/j.blre.2017.08.010. View

He L, Li H, Wu A, Peng Y, Shu G, Yin G . Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019; 18(1):176. PMC: 6892141. DOI: 10.1186/s12943-019-1109-9. View

Langfelder P, Horvath S . WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9:559. PMC: 2631488. DOI: 10.1186/1471-2105-9-559. View

10.

Weng H, Huang H, Wu H, Qin X, Zhao B, Dong L . METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA mA Modification. Cell Stem Cell. 2018; 22(2):191-205.e9. PMC: 5860916. DOI: 10.1016/j.stem.2017.11.016. View

11.

Swaminathan M, Wang E . Novel therapies for AML: a round-up for clinicians. Expert Rev Clin Pharmacol. 2021; 13(12):1389-1400. DOI: 10.1080/17512433.2020.1850255. View

12.

Gregory T, Wald D, Chen Y, Vermaat J, Xiong Y, Tse W . Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009; 2:23. PMC: 2700131. DOI: 10.1186/1756-8722-2-23. View

13.

Knuckles P, Lence T, Haussmann I, Jacob D, Kreim N, Carl S . Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the mA machinery component Wtap/Fl(2)d. Genes Dev. 2018; 32(5-6):415-429. PMC: 5900714. DOI: 10.1101/gad.309146.117. View

14.

Pallante P, Forzati F, Federico A, Arra C, Fusco A . Polycomb protein family member CBX7 plays a critical role in cancer progression. Am J Cancer Res. 2015; 5(5):1594-601. PMC: 4497428. View

15.

Wang P, Doxtader K, Nam Y . Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Mol Cell. 2016; 63(2):306-317. PMC: 4958592. DOI: 10.1016/j.molcel.2016.05.041. View

16.

Graf C, Heidel F, Tenzer S, Radsak M, Solem F, Britten C . A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood. 2006; 109(7):2985-8. DOI: 10.1182/blood-2006-07-032839. View

17.

Zhang H, Deng T, Liu R, Ning T, Yang H, Liu D . CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020; 19(1):43. PMC: 7045485. DOI: 10.1186/s12943-020-01168-8. View

18.

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A . A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-1191. PMC: 6475503. DOI: 10.1038/s41591-018-0085-8. View

19.

Zhang S, Zhang E, Long J, Hu Z, Peng J, Liu L . Immune infiltration in renal cell carcinoma. Cancer Sci. 2019; 110(5):1564-1572. PMC: 6501001. DOI: 10.1111/cas.13996. View

20.

Zhang L, Chen X, Liu X, Kline D, Teague R, Gajewski T . CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013; 123(5):1999-2010. PMC: 3635717. DOI: 10.1172/JCI63980. View